Respiratory syncytial virus infection

Lancet

Volumn 354, Issue 9181, 1999, Pages 847-852

  Simoes, Eric A F ^a  

^a Box C238 Sch Pharm Univ C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ADULT; AGED; CLINICAL FEATURE; HUMAN; IMMUNE RESPONSE; INFANT; LOWER RESPIRATORY TRACT INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW;

EID: 0033523417     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)80040-3     Document Type: Review

References (52)

1. Morris JA Jr, Blunt RE, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med. 92:1956;544-550.
2. Chanock RM, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent: I, isolation, properties and characterization. Am J Hyg. 66:1957;281-290.
3. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q. 45:1992;180-191.
4. Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization: I, a field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 89:1969;435-448.
5. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med. 329:1993;1524-1530.
6. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537.
7. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 140:1986;543-546.
8. Ukkonen P, Hovi T, Von Bonsdorff CH, et al. Age specific prevalence of complement fixing antibodies to sixteen viral antigens: a computer analysis of 58 500 patients covering a period of 8 years. J Med Virol. 13:1984;131-148.
9. Dowell SF, Anderson LJ, Gary HE Jr, et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis. 174:1996;456-462.
10. Falsey AR, Cunningham CK, Barker WH, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 172:1995;389-394.
11. Selwyn BJ. The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. on behalf of the Rev Infect Dis. 12:1990;S870-S888. (suppl 8).
12. Weber MW, Mulholland EK, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health. 3:1998;268-280.
13. Cherian T, Simoes EA, Steinhoff MC, et al. Bronchiolitis in tropical south India. Am J Dis Child. 144:1990;1026-1030.
14. Collins PL, Hill MG, Camargo E, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci USA. 92:1995;11563-11567.
15. Cranage MP, Gardner PS. Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections. J Med Virol. 5:1980;161-170.
16. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T-lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 88:1991;1026-1033.
17. Graham BS. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. Am J Respir Crit Care Med. 152:1995;S63-66.
18. Hammer J, Numa A, Newth CJ. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol. 23:1997;176-183.
19. Kim KK, Frankel LR. The need for inotropic support in a subgroup of infants with severe life-threatening respiratory syncytial virus infection. J Invest Med. 45:1997;469-473.
20. Kneyber MC, Brandenburg AH, de Groot R, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr. 157:1998;331-335.
21. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis. 175:1997;814-820.
22. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. Eur J Pediatr. 157:1998;215-220.
23. Weber MW, Dackour R, Usen S, et al. The clinical spectrum of respiratory syncytial virus disease in The Gambia. Pediatr Infect Dis J. 17:1998;224-230.
24. Brandenburg AH, Jeannet PY, Steensel-Moll HA, et al. Local variability in respiratory syncytial virus disease severity. Arch Dis Child. 77:1997;410-414.
25. Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis. 177:1998;463-466.
26. Wang EE, Law BJ, Boucher FD, et al. Pediatric Investigation Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial virus lower respiratory tract infection. J Pediatr. 129:1996;390-395.
27. Kellner JD, Ohlsson A, Gadomski AM, Wang EL. Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis. Arch Pediatr Adolesc Med. 150:1996;1166-1172.
28. Sanchez I, De Koster J, Powell RE, et al. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. J Pediatr. 122:1993;145-151.
29. Menon K, Sutcliffe T, Klassen TP. A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J Pediatr. 126:1995;1004-1007.
30. Roosevelt G, Sheehan K, Grupp-Phelan J, et al. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet. 348:1996;292-295.
31. De Boeck K, Van der Aa N, Van Lierde S, et al. Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study. J Pediatr. 131:1997;919-921.
32. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection. N Engl J Med. 308:1983;1443-1447.
33. Randolph AG, Wang EEL. Ribavirin for respiratory syncytial virus lower respiratory tract infection. Arch Pediatr Adolesc Med. 150:1996;942-947.
34. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med. 325:1991;24-29.
35. Meert KL, Sarnaik AP, Gelmini MJ, Lich-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double blind, randomized clinical trial. Crit Care Med. 22:1994;566-572.
36. Moler FW, Steinhart CM, Ohmit SE, Stidham GL. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr. 128:1996;422-428.
37. Law B, Wang EEL, MacDonald N, et al. Does ribavirin impact on the hospital course of children with respiratory syncytial virus infection? An analysis using the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) RSV database. Pediatrics. 99:1997;E7.
38. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transpl. 16:1995;393-399.
39. Breese JS, Fischer M, Dowell SF, et al. Vitamin A therapy for children with respiratory syncytial virus infection: a multicenter trial in the United States. Pediatr Infect Dis J. 15:1996;777-782.
40. Rodriguez WJ, Gruber W, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 100:1997;937-942.
41. Rimensberger PC, Burek-Kozlowska A, Morell A, et al. Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants. Pediatr Infect Dis J. 15:1996;209-216.
42. Karron RA, Wright PF, Crowe JE Jr, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 176:1997;1428-1436.
43. Crowe JE Jr, Bui PT, Firestone CY, et al. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates. J Infect Dis. 173:1996;829-839.
44. Pringle CR, Filipiuk AH, Robinson BS, et al. Immunogenicity and pathogenicity of a triple temperature sensitive modified respiratory syncytial virus in adult volunteers. Vaccine. 11:1993;473-478.
45. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 11:1998;430-439.
46. Tristram DA, Welliver RC, Mohar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis. 167:1993;191-195.
47. Groothuis JR, King SJ, Hogerman DA, et al. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis. 177:1998;467-469.
48. Piedra PA, Grace S, Jewell A, et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 17:1998;217-224.
49. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics. 99:1997;93-99.
50. Simoes EAF, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. 133:1998;492-499.
51. Simoes EAF, Groothuis JR, Tristam DA, et al. Respiratory syncytial virus immune globulin prevents acute otitis media in high-risk children. J Pediatr. 129:1996;214-219.
52. Johnson S, Oliver C, Prince G, et al. Development of a humanized monoclonal antibody (MED-493) with potent in vitro and in vivo activity against respiratory syncytial virus (RSV). J Infect Dis. 176:1997;1215-1224.